The COVID-19 Seroconversion Panel consists of 14 members with each member containing 1 vial of 1.0 mL of human plasma. Panel members collected in this longitudinal series are from a single donor during the progression of a SARS-CoV-2 infection. This panel illustrates the onset and decline of IgM and IgG SARS-CoV-2 virus antibody titers over a period of 87 days. Panel members are undiluted, naturally occurring plasma samples collected in 4% sodium citrate. Units were aseptically filtered. No preservative has been added. All panel members are ready to use.
This Seroconversion Panel (SCP) is intended for use by diagnostic manufacturers and researchers during assay development, evaluation, troubleshooting COVID-19 test methods.
STORAGE AND STABILITY
Panel members should be stored at -20°C or colder. Thaw samples at room temperature and mix gently by inversion before usage. Avoid foaming, contamination and repeated freeze and thaw cycles. After usage, return immediately to storage conditions.
WARNINGS AND PRECAUTIONS
All blood products should be treated as potentially infectious. All human source materials used in the manufacture of this SCP were tested and found negative for all US FDA required relevant transfusion-transmitted infections as described in 21 CFR 610.40. No known test methods can offer assurance that products derived from human blood will not transmit infectious agents; appropriate care should be taken in the use of this product. These materials should be disposed in accordance to applicable local or national regulations. Waste must be disposed in a secured manner.
It is of the utmost importance that proper biosafety guidelines are followed by clinical laboratories when handling samples from suspected COVID-19 patients. The laboratory biosafety guidance related to the coronavirus disease issued by the World Health Organization should be taken into account where applicable.1
All panel members used in the preparation of this product have been tested and found negative by tests for antibodies to HIV 1/2, HCV and non-reactive for HBsAg. Pooled samples were found non-reactive for HIV-1 RNA, HBV DNA and HCV RNA by Nucleic Acid Test. All testing is performed with kits approved by the FDA. All samples are non-reactive for SARS-CoV-2 by Nucleic Acid Test.
The donor has been tested and found negative for syphilis according to FDA guidelines. All samples are collected under informed consent and an approved IRB protocol. All member units were collected at an FDA licensed donor center within the US.
Blood type: B
SARS-CoV-2 antibody reactivity is measured for each panel member with LIAISON SARS-CoV-2 51/52 lgG assay-DiaSorin, Inc., SARS-CoV-2 lgG ELISA Test Kit and SARS-CoV-2 lgM ELISA Test Kit by Gold Standard Diagnostics, Anti-SARS-CoV-2 (IgG) ELISA kit by Progenika Biopharma SA, VITROS Anti-SARS-CoV-2 lgG test and VITROS Anti-SARS-CoV-2 Total test by Ortho-Clinical Diagnostics, Inc.
LIMITATIONS AND RESTRICTIONS
This panel is for Research Use Only and not intended for human or animal diagnostics, or for therapeutic purposes. Each laboratory has the responsibility to ascertain the suitability of the SCP for its particular application and to establish their own guidelines for interpretation of results. Data is provided for informational purposes only. Access Biologicals does not claim that others can duplicate these test results exactly.